NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
25 hedge funds and large institutions have $19.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
21% more capital invested
Capital invested by funds: $16M → $19.3M (+$3.31M)
14% more funds holding
Funds holding: 22 → 25 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.46M |
| 2 |
Squarepoint
New York
|
+$417K |
| 3 |
Renaissance Technologies
New York
|
+$187K |
| 4 |
PPCM
Pillar Pacific Capital Management
Pacifica,
California
|
+$131K |
| 5 |
Jane Street
New York
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$99K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$85K |
| 3 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$72K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$38K |
| 5 |
Millennium Management
New York
|
-$34.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
JP Morgan Chase
New York
| – | -$99K | -687 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$85K | -591 | Closed |
|
|
FAIM
28
Financial Advocates Investment Management
Olympia,
Washington
| – | -$72K | -500 | Closed |
|
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$38K | -271 | Closed |
|
|
AP
30
Americana Partners
Houston,
Texas
| – | -$1K | -13 | Closed |
|
|
AA
31
Ancora Advisors
Cleveland,
Ohio
| – | -$1K | -5 | Closed |
|
NBSE Hedge Fund Activity: Q1 2020 in Review
25 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2020, worth a combined $19.3M — up 21% from $16M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NBSE positions and 6 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $2.46M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $99K sold.
- 25 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2020, up from 22 in Q4 2019.
- Funds reported $19.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2020, up 21% quarter-over-quarter.
- 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2020 and 6 closed out, a net change of +4 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2020 was OrbiMed, an estimated $2.46M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2020 was JP Morgan Chase, an estimated $99K sold.
Based on aggregated 13F filings for Q1 2020.